Please login to the form below

interferon beta-1a

This page shows the latest interferon beta-1a news and features for those working in and with pharma, biotech and healthcare.

Ocrevus off to a flying start as Roche raises 2017 forecasts

The take-up of the drug has been buoyed by trials showing that the drug outperformed Merck KGaA's MS stalwart Rebif (interferon beta-1a) in two relapsing MS phase III

Latest news

Roche sets disruptive price for new MS drug Ocrevus in US

Ocrevus' clinical profile has already caught the attention of MS patients and their doctors, with trials showing that the drug outperformed Merck KGaA's Rebif (interferon beta-1a) in two relapsing
Avelumab costs peg back profit at Merck KGaA

Pfizer-partnered avelumab is central to Merck's plans to revitalise its healthcare business, currently under pressure as top-selling Rebif (interferon beta-1a) - an injectable treatment for multiple sclerosis - tries
FDA delays verdict on Roche's MS drug Ocrevus

Ocrevus is the first investigational medicine with the potential to treat both forms, outperforming Merck KGaA's Rebif (interferon beta-1a) in the two relapsing multiple sclerosis phase III trials and
Merck's pharma unit faces tougher 2017 as fertility boost recedes

2017". That's important because Gonal-f has buoyed Merck's healthcare unit in the face of declining sales for its two biggest products - injectable multiple sclerosis therapy Rebif (interferon ... 1a) and colorectal cancer therapy Erbitux (cetuximab) -
Fertility drugs drive healthcare growth at Merck KGaA

Merck makes the most of its portfolio of mature drugs, and top-seller Rebif (interferon beta-1a) for relapsing-remitting multiple sclerosis held up fairly well despite fierce competition from newer,

More from news
Approximately 1 fully matching, plus 50 partially matching documents found.

Latest Intelligence

Tackling a formidable foe

Formidable foe. “With Rebif (interferon beta-1a), Merck’s legacy MS therapy approved in Europe 20 years ago, one of the innovations is the ability to have auto-injectors and devices

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account director: Competitive salary and bonus scheme

Account Director: £Competitive Salary

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Medical Writer or Lead Medical Writer: £Competitive Salary

Account Director, Healthcare Communications: Salary TBC

Publications director: Competitive salary and bonus scheme

Scientific Director: £60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more

Experienced medical editor: Competitive salary and bonus scheme

Account Manager (PR): Great Benefits

Account Director, Medical Education: Salary TBC

Digital Associate Director - Medcomms: £65000 - £80000 per annum

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Brand Manager - Medium Global Pharma Company: £Competitive Financial Package

Senior Medical Writer, MedComms Agency: Salary TBC

Account Manager: £Competitive Salary

Group Director of Medical Affairs and Scientific Strategy, Medic...: Substantial six figure package

Senior External Communications Lead: £Competitive Salary

Subscribe to our email news alerts

PMHub

Add my company

Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Novo Nordisk awakens its ‘Sleeping Beauty’: Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?: Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019: OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...